- Completed
Phase II HOVON 143 Study: Ixazomib, Dara and Low Dose Dex in Intermediate-Fit Patients NDMM
Updated: Sep 22, 2022
Phase II HOVON 143 Study
Trial Update 63rd ASH Annual Meeting
80 Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study
Program: Oral and Poster Abstracts
Type: Oral
Session: 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Phase 2 and 3 Trials in Myeloma
Hematology Disease Topics & Pathways:
Biological, Clinical Trials, Non-Biological, Elderly, Plasma Cell Disorders, Clinical Research, Diseases, Immunotherapy, Therapies, Adverse Events, Lymphoid Malignancies, Study Population
Saturday, December 11, 2021: 9:45 AM
Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study
Volume 39, Issue 25, 2021
Abstract
HOVON HO143 MM
Title: Efficacy and tolerability of ixazomib, daratumumab and low dose dexamethasone (IDd) followed by ixazomib and daratumumab maintenance therapy until progression for a maximum of 2 years in unfit and frail newly diagnosed multiple myeloma patients; an open-label phase II trial.
Primary objective:
To determine the efficacy, defined as overall response rate (ORR), of 9 cycles of ixazomib, daratumumab and low dose dexamethasone. Overall response will be defined as (stringent) complete response ((s)CR), very good partial (VGPR) response and partial response (PR)
HOVON 143 MM
Title
Efficacy and tolerability of ixazomib, daratumumab and low dose dexamethasone (IDd) followed by ixazomib and daratumumab maintenance therapy until progression for a maximum of 2 years in unfit and frail newly diagnosed multiple myeloma patients; an open-label phase II trial